These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 7483646

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L, Mayzell G, Pedan A, Farrell M, Gilbert T.
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward.
    Tfelt-Hansen PC, Koehler PJ.
    Cephalalgia; 2008 Aug; 28(8):877-86. PubMed ID: 18460007
    [Abstract] [Full Text] [Related]

  • 46. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
    Kellerman D, Kori S, Forst A, Chang J, Febbraro S, Wutann L, Thomas T, Taylor G, Dodick D.
    Cephalalgia; 2012 Jan; 32(2):150-8. PubMed ID: 22174351
    [Abstract] [Full Text] [Related]

  • 47. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
    Aellig WH, Rosenthaler J.
    Eur J Clin Pharmacol; 1986 Jan; 30(5):581-4. PubMed ID: 3758146
    [Abstract] [Full Text] [Related]

  • 48. Dihydroergotamine and its use in migraine with posterior fossa symptoms.
    Whyte CA, Stillman MJ, Tepper SJ.
    Headache; 2010 Oct; 50(9):1419-23. PubMed ID: 20533960
    [Abstract] [Full Text] [Related]

  • 49. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
    Lipton RB, Albrecht D, Bermudez M, Hu J, Hussey E, Levy J.
    Headache; 2024 Mar; 64(3):266-275. PubMed ID: 38413540
    [Abstract] [Full Text] [Related]

  • 50. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P.
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M, Gelfand AA, Riggins NY, Shiboski S, Schankin C, Goadsby PJ.
    Neurology; 2016 Mar 01; 86(9):856-9. PubMed ID: 26843569
    [Abstract] [Full Text] [Related]

  • 53. Open label study of intranasal sumatriptan (Imigran) for footballer's headache.
    McCrory P, Heywood J, Ugoni A.
    Br J Sports Med; 2005 Aug 01; 39(8):552-4. PubMed ID: 16046342
    [Abstract] [Full Text] [Related]

  • 54. [Transformed migraine--chronic daily headache].
    Bøe MG, Monstad P.
    Tidsskr Nor Laegeforen; 1999 Nov 30; 119(29):4311-3. PubMed ID: 10667127
    [Abstract] [Full Text] [Related]

  • 55. Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.
    Barthel W, Glusa E, Koth W.
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb 30; 25(2):63-9. PubMed ID: 2881898
    [Abstract] [Full Text] [Related]

  • 56. [Transient global amnesia following the use of ergots in the treatment of migraine].
    Gil-Martínez T, Galiano R.
    Rev Neurol; 1987 Feb 30; 39(10):929-31. PubMed ID: 15573308
    [Abstract] [Full Text] [Related]

  • 57. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD, Dahlöf CG, Brandes JL, Agosti R, Jones MW, Barrett PS.
    Clin Ther; 2005 Apr 30; 27(4):407-17. PubMed ID: 15922814
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.